The Changing Face of HDL and the Best Way to Measure It.

BACKGROUND HDL cholesterol (HDL-C) is a commonly used lipid biomarker for assessing cardiovascular health. While a central focus has been placed on the role of HDL in the reverse cholesterol transport (RCT) process, our appreciation for the other cardioprotective properties of HDL continues to expand with further investigation into the structure and function of HDL and its specific subfractions. The development of novel assays is empowering the research community to assess different aspects of HDL function, which at some point may evolve into new diagnostic tests. CONTENT This review discusses our current understanding of the formation and maturation of HDL particles via RCT, as well as the newly recognized roles of HDL outside RCT. The antioxidative, antiinflammatory, antiapoptotic, antithrombotic, antiinfective, and vasoprotective effects of HDL are all discussed, as are the related methodologies for assessing these different aspects of HDL function. We elaborate on the importance of protein and lipid composition of HDL in health and disease and highlight potential new diagnostic assays based on these parameters. SUMMARY Although multiple epidemiologic studies have confirmed that HDL-C is a strong negative risk marker for cardiovascular disease, several clinical and experimental studies have yielded inconsistent results on the direct role of HDL-C as an antiatherogenic factor. As of yet, our increased understanding of HDL biology has not been translated into successful new therapies, but will undoubtedly depend on the development of alternative ways for measuring HDL besides its cholesterol content.

[1]  J. Otvos,et al.  Small and medium sized HDL particles are protectively associated with coronary calcification in a cross-sectional population-based sample. , 2016, Atherosclerosis.

[2]  M. Connelly,et al.  High-density lipoprotein and inflammation in cardiovascular disease. , 2016, Translational research : the journal of laboratory and clinical medicine.

[3]  M. Budoff,et al.  Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients With Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA]). , 2016, The American journal of cardiology.

[4]  J. Polak,et al.  Concentration of Smaller High‐Density Lipoprotein Particle (HDL‐P) Is Inversely Correlated With Carotid Intima Media Thickening After Confounder Adjustment: The Multi Ethnic Study of Atherosclerosis (MESA) , 2016, Journal of the American Heart Association.

[5]  A. Gotto,et al.  Speciated High-Density Lipoprotein Biogenesis and Functionality , 2016, Current Atherosclerosis Reports.

[6]  T. Hornemann,et al.  Decreased phosphatidylcholine plasmalogens--A putative novel lipid signature in patients with stable coronary artery disease and acute myocardial infarction. , 2016, Atherosclerosis.

[7]  E. Grapsa,et al.  Association of lipid profile with serum PON1 concentration in patients with chronic kidney disease , 2016, Renal failure.

[8]  G. Franceschini,et al.  Protective Effects of HDL Against Ischemia/Reperfusion Injury , 2016, Front. Pharmacol..

[9]  P. Ridker,et al.  Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial , 2015, Circulation.

[10]  M. Gruchała,et al.  PON-1 Activity and Plasma 8-Isoprostane Concentration in Patients with Angiographically Proven Coronary Artery Disease , 2015, Oxidative medicine and cellular longevity.

[11]  D. Rader,et al.  Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib. , 2015, Journal of the American College of Cardiology.

[12]  N. Schneiderman,et al.  HDL cholesterol and stroke risk: The Multi-Ethnic Study of Atherosclerosis. , 2015, Atherosclerosis.

[13]  R. Erbel,et al.  Defects of High-Density Lipoproteins in Coronary Artery Disease Caused by Low Sphingosine-1-Phosphate Content: Correction by Sphingosine-1-Phosphate-Loading. , 2015, Journal of the American College of Cardiology.

[14]  P. Ridker,et al.  Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The JUPITER Trial , 2015 .

[15]  C. Shear,et al.  Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial , 2015, Journal of the American Heart Association.

[16]  D. Rader,et al.  Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study , 2015, The lancet. Diabetes & endocrinology.

[17]  A. Pitt,et al.  Oxidative lipidomics coming of age: advances in analysis of oxidized phospholipids in physiology and pathology. , 2015, Antioxidants & redox signaling.

[18]  M. Malkoç,et al.  Pleiotropic eff ects of HDL subfractions and HDL-associated enzymes on protection against coronary artery disease , 2015, Acta cardiologica.

[19]  D. Rader,et al.  High-Density Lipoprotein (HDL) Phospholipid Content and Cholesterol Efflux Capacity Are Reduced in Patients With Very High HDL Cholesterol and Coronary Disease , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[20]  G. Franceschini,et al.  Acquired lecithin:cholesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease , 2015, Journal of internal medicine.

[21]  B. Vergès Pathophysiology of diabetic dyslipidaemia: where are we? , 2015, Diabetologia.

[22]  T. Murohara,et al.  Relation between paradoxical decrease in high-density lipoprotein cholesterol levels after statin therapy and adverse cardiovascular events in patients with acute myocardial infarction. , 2015, The American journal of cardiology.

[23]  J. Genest,et al.  High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk , 2015, BBA clinical.

[24]  A. Tall,et al.  Cholesterol, inflammation and innate immunity , 2015, Nature Reviews Immunology.

[25]  A. Khera,et al.  HDL cholesterol efflux capacity and incident cardiovascular events. , 2014, The New England journal of medicine.

[26]  Guohua Song,et al.  Psoriasis decreases the anti-oxidation and anti-inflammation properties of high-density lipoprotein. , 2014, Biochimica et biophysica acta.

[27]  H. Berrougui,et al.  Alteration of HDL functionality and PON1 activities in acute coronary syndrome patients. , 2014, Clinical biochemistry.

[28]  E. Soriano,et al.  Altered lipidome and antioxidative activity of small, dense HDL in normolipidemic rheumatoid arthritis: relevance of inflammation. , 2014, Atherosclerosis.

[29]  G. Jarvik,et al.  Quantification of HDL particle concentration by calibrated ion mobility analysis. , 2014, Clinical chemistry.

[30]  P. Wolf,et al.  Antipsoriatic treatment extends beyond the skin: recovering of high‐density lipoprotein function , 2014, Experimental dermatology.

[31]  J. Kastelein,et al.  Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. , 2014, British journal of clinical pharmacology.

[32]  G. Norata,et al.  HDL in innate and adaptive immunity. , 2014, Cardiovascular research.

[33]  M. Phillips Molecular Mechanisms of Cellular Cholesterol Efflux* , 2014, The Journal of Biological Chemistry.

[34]  Sarah Parish,et al.  Effects of extended-release niacin with laropiprant in high-risk patients. , 2014, The New England journal of medicine.

[35]  I. Holme,et al.  The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial. , 2014, European heart journal.

[36]  V. Falk,et al.  TAVI in a low left main coronary artery ostium and wide aortic sinus of Valsava. , 2014, European heart journal.

[37]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[38]  J. Suico,et al.  Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults , 2014, The Journal of pharmacy and pharmacology.

[39]  B. Kingwell,et al.  HDL-targeted therapies: progress, failures and future , 2014, Nature Reviews Drug Discovery.

[40]  Kirsty Minton Cell migration: Coordinating calcium signalling , 2014, Nature Reviews Molecular Cell Biology.

[41]  R. Nieuwland,et al.  Co-isolation of extracellular vesicles and high-density lipoproteins using density gradient ultracentrifugation , 2014, Journal of extracellular vesicles.

[42]  E. Latz,et al.  High density lipoprotein mediates anti-inflammatory transcriptional reprogramming of macrophages via the transcriptional repressor ATF3 , 2013, Nature Immunology.

[43]  A. Nègre-Salvayre,et al.  Small, Dense High-Density Lipoprotein-3 Particles Are Enriched in Negatively Charged Phospholipids: Relevance to Cellular Cholesterol Efflux, Antioxidative, Antithrombotic, Anti-Inflammatory, and Antiapoptotic Functionalities , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[44]  A. Kontush,et al.  Unraveling the complexities of the HDL lipidome1 , 2013, Journal of Lipid Research.

[45]  Tanya M. Teslovich,et al.  Discovery and refinement of loci associated with lipid levels , 2013, Nature Genetics.

[46]  David C. Anderson,et al.  Extended-Release Niacin Therapy and Risk of Ischemic Stroke in Patients With Cardiovascular Disease: The Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides Impact on Global Health Outcome (AIM–HIGH) Trial , 2013, Stroke.

[47]  P. Ridker,et al.  Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients: A Meta-Analysis , 2013, Circulation.

[48]  G. Franceschini,et al.  Inflammation impairs eNOS activation by HDL in patients with acute coronary syndrome. , 2013, Cardiovascular research.

[49]  P. Ridker,et al.  High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy , 2013, Circulation.

[50]  J. Varshosaz,et al.  Association between HDL particles size and myeloperoxidase/ paraoxonase-1 (MPO/PON1) ratio in patients with acute coronary syndrome. , 2013, Acta medica Iranica.

[51]  J. Voss,et al.  The secondary structure of apolipoprotein A-I on 9.6-nm reconstituted high-density lipoprotein determined by EPR spectroscopy , 2013, The FEBS journal.

[52]  K. Koh,et al.  How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol. , 2013, International journal of cardiology.

[53]  K. Moore,et al.  Dysfunctional HDL takes its toll in chronic kidney disease. , 2013, Immunity.

[54]  M. Saemann,et al.  Inflammation alters HDL composition and function: implications for HDL-raising therapies. , 2013, Pharmacology & therapeutics.

[55]  R. Hegele,et al.  HDL deficiency due to a new insertion mutation (ApoA-INashua) and review of the literature. , 2013, Journal of clinical lipidology.

[56]  G. Norata,et al.  High-Density Lipoprotein Subfractions - What the Clinicians Need to Know , 2013, Cardiology.

[57]  Jun Ren,et al.  High-density lipoprotein of patients with Type 2 Diabetes Mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1-phosphate , 2013, Cardiovascular Diabetology.

[58]  Markus Abt,et al.  Effects of dalcetrapib in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[59]  K. Huber,et al.  Cardiovascular disease risk reduction by raising HDL cholesterol – current therapies and future opportunities , 2012, British journal of pharmacology.

[60]  K. Zangger,et al.  Myeloperoxidase-derived chlorinating species induce protein carbamylation through decomposition of thiocyanate and urea: novel pathways generating dysfunctional high-density lipoprotein. , 2012, Antioxidants & redox signaling.

[61]  R. Birner-Gruenberger,et al.  Psoriasis alters HDL composition and cholesterol efflux capacity[S] , 2012, Journal of Lipid Research.

[62]  E. Eren,et al.  High Density Lipoprotein and it’s Dysfunction , 2012, The open biochemistry journal.

[63]  J. Ordóñez‐Llanos,et al.  Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution. , 2012, The American journal of cardiology.

[64]  D. Elashoff,et al.  Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. , 2012, Arthritis and rheumatism.

[65]  L. Joosten,et al.  High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study , 2012, Arthritis Research & Therapy.

[66]  N. Knowlton,et al.  Apolipoprotein-defined lipoprotein abnormalities in rheumatoid arthritis patients and their potential impact on cardiovascular disease , 2012, Scandinavian journal of rheumatology.

[67]  W. Hörl,et al.  Serum amyloid A in uremic HDL promotes inflammation. , 2012, Journal of the American Society of Nephrology : JASN.

[68]  Swneke D. Bailey,et al.  The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. , 2012, Biochimica et biophysica acta.

[69]  N. Webb,et al.  Nascent HDL formation in hepatocytes and role of ABCA1, ABCG1, and SR-BI[S] , 2012, Journal of Lipid Research.

[70]  B. Nordestgaard,et al.  LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. , 2012, The Journal of clinical endocrinology and metabolism.

[71]  William Weintraub,et al.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.

[72]  A. Clarke,et al.  Effects of Wnt3A and mechanical load on cartilage chondrocyte homeostasis , 2011, Arthritis research & therapy.

[73]  O. Yang,et al.  A biochemical fluorometric method for assessing the oxidative properties of HDL[S] , 2011, Journal of Lipid Research.

[74]  Ming-Dauh Wang,et al.  Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. , 2011, JAMA.

[75]  R. Birner-Gruenberger,et al.  Uremia alters HDL composition and function. , 2011, Journal of the American Society of Nephrology : JASN.

[76]  G. Moneta Correction for Feig et al., HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells , 2011, Proceedings of the National Academy of Sciences.

[77]  A. Akhmedov,et al.  Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. , 2011, The Journal of clinical investigation.

[78]  E. Schaefer,et al.  Metabolic and functional relevance of HDL subspecies , 2011, Current opinion in lipidology.

[79]  B. Nordestgaard,et al.  S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease , 2011, Lipids in Health and Disease.

[80]  A. Nègre-Salvayre,et al.  Oxidized LDLs trigger endoplasmic reticulum stress and autophagy: Prevention by HDLs , 2011, Autophagy.

[81]  A. Nègre-Salvayre,et al.  HDLs inhibit endoplasmic reticulum stress and autophagic response induced by oxidized LDLs , 2011, Cell Death and Differentiation.

[82]  M. Kaplan,et al.  The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus , 2011, Arthritis research & therapy.

[83]  Robert L Wilensky,et al.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.

[84]  W. Hörl,et al.  The versatility of HDL: a crucial anti‐inflammatory regulator , 2010, European journal of clinical investigation.

[85]  Koichi Sato,et al.  Role of sphingosine 1-phosphate in anti-atherogenic actions of high-density lipoprotein. , 2010, World journal of biological chemistry.

[86]  L. Tian,et al.  The relationship between high density lipoprotein subclass profile and plasma lipids concentrations , 2010, Lipids in Health and Disease.

[87]  R. Hegele,et al.  Complete Apo AI deficiency in an Iraqi Mandaean family: case studies and review of the literature. , 2010, Journal of clinical lipidology.

[88]  Tanya M. Teslovich,et al.  Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[89]  E. Schaefer,et al.  Marked HDL deficiency and premature coronary heart disease , 2010, Current opinion in lipidology.

[90]  P. Barter,et al.  Nonenzymatic Glycation Impairs the Antiinflammatory Properties of Apolipoprotein A-I , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[91]  M. Olivier,et al.  Integrated approach for the comprehensive characterization of lipoproteins from human plasma using FPLC and nano-HPLC-tandem mass spectrometry. , 2010, Physiological genomics.

[92]  Costantina Manes,et al.  Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy , 2010, Circulation.

[93]  Florian Kronenberg,et al.  Emerging risk factors and markers of chronic kidney disease progression , 2009, Nature Reviews Nephrology.

[94]  D. Sviridov,et al.  Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux , 2009, Circulation.

[95]  W. Hueb,et al.  In Vitro Simultaneous Transfer of Lipids to HDL in Coronary Artery Disease and in Statin Treatment , 2009, Lipids.

[96]  A. Daugherty,et al.  Scavenger Receptor BI Protects against Septic Death through Its Role in Modulating Inflammatory Response* , 2009, The Journal of Biological Chemistry.

[97]  Shuiping Zhao,et al.  Association of plasma apolipoprotein AV with lipid profiles in patients with acute coronary syndrome. , 2009, Atherosclerosis.

[98]  S. Hajduk,et al.  Membrane Permeabilization by Trypanosome Lytic Factor, a Cytolytic Human High Density Lipoprotein* , 2009, Journal of Biological Chemistry.

[99]  T. Mogensen Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses , 2009, Clinical Microbiology Reviews.

[100]  A. Remaley,et al.  Lecithin: cholesterol acyltransferase--from biochemistry to role in cardiovascular disease. , 2009, Current opinion in endocrinology, diabetes, and obesity.

[101]  M. Couturier,et al.  Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I , 2009, Journal of cellular and molecular medicine.

[102]  N. Wareham,et al.  High-Density Lipoprotein Particle Size and Concentration and Coronary Risk , 2009, Annals of Internal Medicine.

[103]  D. Sviridov,et al.  Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque , 2008, Circulation research.

[104]  S. Hammad,et al.  High Density Lipoprotein-associated Sphingosine 1-Phosphate Promotes Endothelial Barrier Function* , 2008, Journal of Biological Chemistry.

[105]  J. Liao HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. , 2008, Current atherosclerosis reports.

[106]  B. Levkau Sphingosine-1-phosphate in the regulation of vascular tone: a finely tuned integration system of S1P sources, receptors, and vascular responsiveness. , 2008, Circulation research.

[107]  L. Badimón,et al.  Prostacyclin induction by high-density lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: Effect of simvastatin , 2008, Thrombosis and Haemostasis.

[108]  Børge G Nordestgaard,et al.  Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. , 2008, JAMA.

[109]  S. Moestrup,et al.  A Haptoglobin-Hemoglobin Receptor Conveys Innate Immunity to Trypanosoma brucei in Humans , 2008, Science.

[110]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events , 2008 .

[111]  A. Tall,et al.  Cholesterol efflux pathways and other potential mechanisms involved in the athero‐protective effect of high density lipoproteins , 2008, Journal of internal medicine.

[112]  F. D. de Beer,et al.  SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. , 2008, The Journal of clinical investigation.

[113]  S. Moestrup,et al.  Hemoglobin Is a Co-Factor of Human Trypanosome Lytic Factor , 2007, PLoS pathogens.

[114]  M. Couturier,et al.  Preferential Sphingosine-1-Phosphate Enrichment and Sphingomyelin Depletion Are Key Features of Small Dense HDL3 Particles: Relevance to Antiapoptotic and Antioxidative Activities , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[115]  Subramaniam Pennathur,et al.  Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. , 2007, The Journal of clinical investigation.

[116]  N. Brunetti,et al.  Acute phase proteins in patients with acute coronary syndrome: Correlations with diagnosis, clinical features, and angiographic findings. , 2007, European journal of internal medicine.

[117]  Kimmo Kaski,et al.  The inherent accuracy of 1H NMR spectroscopy to quantify plasma lipoproteins is subclass dependent. , 2007, Atherosclerosis.

[118]  P. Barter,et al.  The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase , 2007, Diabetologia.

[119]  A. Kontush,et al.  Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis , 2006, Pharmacological Reviews.

[120]  G. Walldius,et al.  The apoB/apoA‐I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid‐lowering therapy – a review of the evidence , 2006, Journal of internal medicine.

[121]  H. Bloomfield,et al.  Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial , 2006, Circulation.

[122]  S. Hajduk,et al.  Serum Resistance-Associated Protein Blocks Lysosomal Targeting of Trypanosome Lytic Factor in Trypanosoma brucei , 2006, Eukaryotic Cell.

[123]  E. D. de Faria,et al.  A normotriglyceridemic, low HDL-cholesterol phenotype is characterised by elevated oxidative stress and HDL particles with attenuated antioxidative activity. , 2005, Atherosclerosis.

[124]  S. Hajduk,et al.  Human High Density Lipoproteins Are Platforms for the Assembly of Multi-component Innate Immune Complexes* , 2005, Journal of Biological Chemistry.

[125]  B. Hansel,et al.  Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia , 2005, Diabetologia.

[126]  P. Barter,et al.  Antiinflammatory Properties of HDL , 2004 .

[127]  Polly Matzinger,et al.  Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses , 2004, Nature Reviews Immunology.

[128]  G. Norata,et al.  HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[129]  S. Rusconi,et al.  Reconstituted High-Density Lipoprotein Inhibits Thrombin-Induced Endothelial Tissue Factor Expression Through Inhibition of RhoA and Stimulation of Phosphatidylinositol 3-Kinase but not Akt/Endothelial Nitric Oxide Synthase , 2004, Circulation research.

[130]  M. Elisaf,et al.  Effect of atorvastatin on highdensity lipoprotein cholesteroland its relationship withcoronary events: a subgroupanalysis of the GREekAtorvastatin and Coronary-heart-disease Evaluation (GREACE) Study , 2004, Current medical research and opinion.

[131]  G. Franceschini,et al.  Synthetic High-Density Lipoproteins Exert Cardioprotective Effects in Myocardial Ischemia/Reperfusion Injury , 2004, Journal of Pharmacology and Experimental Therapeutics.

[132]  P. Kovanen,et al.  Role of complement activation in atherosclerosis , 2003, Current opinion in lipidology.

[133]  A. Kontush,et al.  Small, Dense HDL Particles Exert Potent Protection of Atherogenic LDL Against Oxidative Stress , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[134]  A. Remaley,et al.  Binding and Internalization of Lipopolysaccharide by Cla-1, a Human Orthologue of Rodent Scavenger Receptor B1* , 2003, Journal of Biological Chemistry.

[135]  M. Quon,et al.  High Density Lipoprotein-induced Endothelial Nitric-oxide Synthase Activation Is Mediated by Akt and MAP Kinases* , 2003, The Journal of Biological Chemistry.

[136]  R. Brasseur,et al.  Apolipoprotein L-I is the trypanosome lytic factor of human serum , 2003, Nature.

[137]  G. Franceschini,et al.  High-Density Lipoproteins Protect Isolated Rat Hearts From Ischemia-Reperfusion Injury by Reducing Cardiac Tumor Necrosis Factor-&agr; Content and Enhancing Prostaglandin Release , 2003, Circulation research.

[138]  G. Norata,et al.  Apoptosis and proliferation of endothelial cells in early atherosclerotic lesions: possible role of oxidised LDL. , 2002, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[139]  F. Ruschitzka,et al.  High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men , 2002, Circulation.

[140]  C. Marchionni,et al.  Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity , 2001, Acta Diabetologica.

[141]  A. von Eckardstein,et al.  Suppression of Endothelial Cell Apoptosis by High Density Lipoproteins (HDL) and HDL-associated Lysosphingolipids* , 2001, The Journal of Biological Chemistry.

[142]  S. Hajduk,et al.  Haptoglobin-related Protein Mediates Trypanosome Lytic Factor Binding to Trypanosomes* , 2001, The Journal of Biological Chemistry.

[143]  S. Reddy,et al.  A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. , 2001, Journal of lipid research.

[144]  Richard G. W. Anderson,et al.  High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase , 2001, Nature Medicine.

[145]  J. Wittes,et al.  Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001, JAMA.

[146]  G. Dagenais,et al.  HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study. , 2000, Atherosclerosis.

[147]  B. Nordestgaard,et al.  Common Cholesteryl Ester Transfer Protein Mutations, Decreased HDL Cholesterol, and Possible Decreased Risk of Ischemic Heart Disease: The Copenhagen City Heart Study , 2000, Circulation.

[148]  Bezafibrate Infarction Prevention study Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.

[149]  K. Tsuchida,et al.  High-Density Lipoproteins Protect Endothelial Cells from Tumor Necrosis Factor-α-Induced Apoptosis , 2000 .

[150]  S.-M. Kim,et al.  Glycation impairs high-density lipoprotein function , 2000, Diabetologia.

[151]  S. Lestavel,et al.  Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[152]  J. Viikari,et al.  Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. , 1999, Atherosclerosis.

[153]  J. Saklatvala,et al.  High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[154]  M. Sata,et al.  Endothelial Cell Apoptosis Induced by Oxidized LDL Is Associated with the Down-regulation of the Cellular Caspase Inhibitor FLIP* , 1998, The Journal of Biological Chemistry.

[155]  A Pasternack,et al.  Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. , 1998, Circulation.

[156]  J. E. Doran,et al.  Reconstituted High Density Lipoprotein (rHDL) Modulates Platelet Activity In Vitro and Ex Vivo , 1998, Thrombosis and Haemostasis.

[157]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[158]  A. van Tol,et al.  Delayed increase in high density lipoprotein-phospholipids after ingestion of a fat load in normolipidemic patients with coronary artery disease. , 1998, Atherosclerosis.

[159]  A. Nègre-Salvayre,et al.  HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[160]  H. Hein,et al.  Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[161]  J. E. Doran,et al.  Differential Effects of Reconstituted High-density Lipoprotein on Coagulation, Fibrinolysis and Platelet Activation during Human Endotoxemia , 1997, Thrombosis and Haemostasis.

[162]  R. Larkins,et al.  Lipoprotein-induced prostacyclin production in endothelial cells and effects of lipoprotein modification. , 1996, The American journal of physiology.

[163]  G. Dagenais,et al.  Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Québec cardiovascular study. , 1996, Atherosclerosis.

[164]  J. Gamble,et al.  High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[165]  T. Wilt,et al.  Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. , 1995, The American journal of cardiology.

[166]  G. Dagenais,et al.  Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study) , 1995, The American journal of cardiology.

[167]  S. Hajduk,et al.  Killing of trypanosomes by the human haptoglobin-related protein. , 1995, Science.

[168]  J. Berliner,et al.  Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.

[169]  A. Tall An overview of reverse cholesterol transport. , 1994, European heart journal.

[170]  F. Fend,et al.  HDL and plasma phospholipids in coronary artery disease. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[171]  S. Hajduk,et al.  Endocytosis of a cytotoxic human high density lipoprotein results in disruption of acidic intracellular vesicles and subsequent killing of African trypanosomes , 1994, The Journal of cell biology.

[172]  C. Abbott,et al.  Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. , 1993, Atherosclerosis.

[173]  K. Emancipator,et al.  In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins , 1992, Infection and immunity.

[174]  A. Tall,et al.  Serum lipoprotein lipid concentration and composition in homozygous and heterozygous patients with cholesteryl ester transfer protein deficiency. , 1991, Atherosclerosis.

[175]  S. G. Rains,et al.  Association of high density lipoprotein cholesterol with plasma lipolytic activity and C-peptide concentration in type 2 diabetes. , 1991, Diabetes research.

[176]  A. Tall,et al.  Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. , 1990, The New England journal of medicine.

[177]  G. Franceschini,et al.  Influence of serum triglycerides on the HDL pattern in normal subjects and patients with coronary artery disease. , 1990, Atherosclerosis.

[178]  Cruickshank Jm Beta-blockers, plasma lipids, and coronary heart disease. , 1990 .

[179]  H. Northoff,et al.  Inhibition of endotoxin-induced activation of human monocytes by human lipoproteins , 1989, Infection and immunity.

[180]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[181]  P. Wilson,et al.  High density lipoprotein cholesterol and mortality. The Framingham Heart Study. , 1988, Arteriosclerosis.

[182]  G. Coetzee,et al.  Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. , 1986, The Journal of biological chemistry.

[183]  A. Tall,et al.  Enrichment of endothelial cell arachidonate by lipid transfer from high density lipoproteins: relationship to prostaglandin I2 synthesis. , 1985, Journal of lipid research.

[184]  J. Witztum,et al.  Plasma Apolipoproteins AI, AII, B, CI, and E Are Glucosylated in Hyperglycemic Diabetic Subjects , 1985, Diabetes.

[185]  R. Strunk,et al.  Human peripheral blood monocyte-derived macrophages produce haemolytically active C3 in vitro. , 1983, Immunology.

[186]  A. Tall,et al.  Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. , 1982, The Journal of biological chemistry.

[187]  E. Lee,et al.  Plasma apolipoprotein B and VLDL-, LDL-, and HDL-cholesterol as risk factors in the development of coronary artery disease in male patients examined by angiography. , 1981, Atherosclerosis.

[188]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.

[189]  G. Miller,et al.  PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE , 1975, The Lancet.

[190]  A. Gotto,et al.  Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. , 2015, Journal of clinical lipidology.

[191]  L. Calabresi,et al.  Structure of HDL: particle subclasses and molecular components. , 2015, Handbook of experimental pharmacology.

[192]  G. Norata,et al.  Emerging role of high density lipoproteins as a player in the immune system. , 2012, Atherosclerosis.

[193]  B. Gersh Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease , 2011 .

[194]  B. Gersh HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial , 2011 .

[195]  M. Phillips,et al.  High density lipoprotein structure-function and role in reverse cholesterol transport. , 2010, Sub-cellular biochemistry.

[196]  G. Moneta,et al.  Major Lipids, Apolipoproteins, and Risk of Vascular Disease , 2010 .

[197]  A. Esteghamati,et al.  LECITHIN: CHOLESTEROL ACYLTRANSFERASE ACTIVITY IS DECREASED IN TYPE 2 DIABETES MELLITUS , 2007 .

[198]  Loyd,et al.  SIMVASTATIN AND NIACIN , ANTIOXIDANT VITAMINS , OR THE COMBINATION FOR THE PREVENTION OF CORONARY DISEASE , 2001 .

[199]  Ames,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[200]  K. Tsuchida,et al.  High-density lipoproteins protect endothelial cells from tumor necrosis factor-alpha-induced apoptosis. , 2000, Biochemical and biophysical research communications.

[201]  R. Ulevitch,et al.  Modulation of endotoxic activity of lipopolysaccharide by high-density lipoprotein. , 1991, Pathobiology : journal of immunopathology, molecular and cellular biology.

[202]  J. Cruickshank Beta-blockers, plasma lipids, and coronary heart disease. , 1990, Circulation.